Crispr Therapeutics AG vs Peloton Interactive Inc — how do they compare? Crispr Therapeutics AG trades at $53.78 (market cap $4.88B), while Peloton Interactive Inc trades at $5.08 (market cap $2.16B). The key difference: Crispr Therapeutics AG is far larger — about 2.3× Peloton Interactive Inc's market cap, and Peloton Interactive Inc is more actively traded (11,369,487 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Peloton Interactive Inc for 37 Days on average.
| CRSP | PTON | |
|---|---|---|
Market Cap | $4.88B | $2.16B |
Volume | 2,861,747 | 11,369,487 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $7.86 |
52-Week Low | $44.34 | $3.71 |
Typical Hold Time | 77 Days | 37 Days |
Enterprise Value | $3.30B | $2.66B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Peloton (PTON) trades at $4.85, down 0.41% on the day, amid a bearish technical signal and mixed earnings history. The company reported its first full-year net profit in 2026 with a 2.58% net income margin, yet revenue has declined from $3.6B in 2022 to $2.4B in 2026. Positive cash flow trends and a new product launch, including a foldable treadmill, aim to revive growth, but negative shareholder equity and high debt levels persist as concerns.
The outlook hinges on execution of the turnaround strategy; upside exists if new products boost subscriptions, but risks include persistent subscriber declines and high leverage. Analyst consensus is a Buy with a $8.00 price target, suggesting significant potential appreciation from current levels if operational improvements continue.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →